The present disclosure relates to an organic light emitting device that includes a substrate; and an organic light emitting diode positioned on the substrate and including a first electrode; a second electrode facing the first electrode; a first emitting material layer including a first dopant of a boron derivative and a first host of an anthracene derivative and positioned between the first and second electrodes; a first electron blocking layer including an electron blocking material of amine derivative and positioned between the first electrode and the first emitting material layer; and a first hole blocking layer including a hole blocking material and positioned between the second electrode and the first emitting material layer, wherein the first host is deuterated.

A condensed cyclic compound represented by Formula 1: ##STR00001##
wherein, in Formula 1, X.sub.11, X.sub.12, and R.sub.11 to R.sub.24 are the same as described in the specification.

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of cancer. ##STR00001##

Provided are compounds having a first ligand L.sub.A of Formula I

##STR00001##

Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of cancer.

##STR00001##

A condensed cyclic compound represented by Formula 1:

##STR00001##

wherein, in Formula 1, X.sub.11, X.sub.12, and R.sub.11 to R.sub.24 are the same as described in the specification.